Bio-Rad Laboratories Class A
About: Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Employees: 8,030
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
41% more call options, than puts
Call options by funds: $6.56M | Put options by funds: $4.65M
15% more capital invested
Capital invested by funds: $5.49B [Q2] → $6.32B (+$829M) [Q3]
4% less first-time investments, than exits
New positions opened: 67 | Existing positions closed: 70
2% less funds holding
Funds holding: 432 [Q2] → 425 (-7) [Q3]
2.95% less ownership
Funds ownership: 85.73% [Q2] → 82.78% (-2.95%) [Q3]
17% less funds holding in top 10
Funds holding in top 10: 6 [Q2] → 5 (-1) [Q3]
21% less repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 164
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
RBC Capital Conor McNamara 29% 1-year accuracy 11 / 38 met price target | 40%upside $481 | Outperform Reiterated | 14 Jan 2025 |
Citigroup Patrick Donnelly 47% 1-year accuracy 15 / 32 met price target | 31%upside $450 | Buy Maintained | 31 Oct 2024 |
Financial journalist opinion
Based on 3 articles about BIO published over the past 30 days
